Institutional review board

DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, August 28, 2023

LOS ANGELES, Aug. 28, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Aug. 28, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • The Law Offices of Frank R. Cruz, Los Angeles

SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. (BTAI) Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Monday, August 28, 2023

NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were adversely affected by alleged securities fraud between December 15, 2021 and June 28, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    BTAI investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioXcel, Seagate, and Baxter and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, August 28, 2023

On December 15, 2021, the Company announced that it had initiated a program to evaluate BXCL501 for the treatment of acute agitation associated with Alzheimer’s disease.

Key Points: 
  • On December 15, 2021, the Company announced that it had initiated a program to evaluate BXCL501 for the treatment of acute agitation associated with Alzheimer’s disease.
  • The Company announced that the program consisted of two randomized, double-blind, placebo-controlled studies: TRANQUILITY II and TRANQUILITY III.
  • Over the course of the Class Period, Baxter’s stock price declined by nearly 50%, eliminating billions of dollars in market capitalization.
  • For more information on the Baxter class action go to: https://bespc.com/cases/BAX

Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!

Retrieved on: 
Monday, August 28, 2023

Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/btai .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/btai .
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • If you suffered a loss in BioXcel you have until September 5, 2023, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

BTAI Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of September 5, 2023 Deadline in Securities Fraud Class Action Lawsuit against BioXcel Therapeutics, Inc. (BTAI)

Retrieved on: 
Sunday, August 27, 2023

The action charges BioXcel with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges BioXcel with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of BioXcel’s materially misleading statements and omissions to the public, BioXcel’s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages BioXcel investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.

ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action – BTAI

Retrieved on: 
Saturday, August 26, 2023

WHAT TO DO NEXT: To join the BioXcel Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=17579 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioXcel Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=17579 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioXcel Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2023 – (NASDAQ: BTAI)

Retrieved on: 
Friday, August 25, 2023

Appointment as lead plaintiff is not required to partake in any recovery.

Key Points: 
  • Appointment as lead plaintiff is not required to partake in any recovery.
  • DEADLINE: September 5, 2023 Shareholders should not delay in registering for this class action.
  • The deadline to seek to be a lead plaintiff is September 5, 2023.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. (BTAI) Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Thursday, August 24, 2023

NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were adversely affected by alleged securities fraud between December 15, 2021 and June 28, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    BTAI investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

DEADLINE ALERT for IBRX, BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Thursday, August 24, 2023

BENSALEM Pa. , Aug. 24, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM Pa. , Aug. 24, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

BTAI Investors Should Contact Robbins LLP About Participating in the Class Action Against BioXcel Therapeutics

Retrieved on: 
Wednesday, August 23, 2023

SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioXcel Therapeutics, Inc. (NASDAQ: BTAI) securities between December 15, 2021 and June 28, 2023.

Key Points: 
  • SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioXcel Therapeutics, Inc. (NASDAQ: BTAI) securities between December 15, 2021 and June 28, 2023.
  • BioXcel is a biopharmaceutical company that claims it uses artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • If you choose to take no action, you can remain an absent class member.